Drug induced liver injury historical perspective

Drug induced liver injury Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Drug Induced Liver Injury from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Drug Induced Liver Injury On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Drug induced liver injury All Images induced liver injury X-ray X-rays induced liver injury Ultrasound Echo & Ultrasound induced liver injury CT CT Images induced liver injury MRI MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Drug induced liver injury
CDC on Drug induced liver injury
Drug induced liver injury in the news
Blogs on Drug induced liver injury
Directions to Hospitals Treating Drug induced liver injury
Risk calculators and risk factors for Drug induced liver injury

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rachita Navara, M.D. [2]

Overview

Drug induced liver injury has been historically underreported.

Historical Perspective

Over the last fifty years, the United States Food and Drug Administration has withdrawn several drugs from the market for causing severe liver injury. Notably in 1997 to 1998, bromfenac and troglitazone were withdrawn from the market for causing severe hepatocellular injury. Drug induced liver injury remains the most frequent single cause of drug withdrawals from the market today.